NCT00813956View on ClinicalTrials.gov

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

gemcitabine plus carboplatin plus BSI-201

iv, 3 week cycles

Trial Locations (2)

19103

PrECOG, Philadelphia

94305

Stanford Comprehensive Cancer Center, Stanford

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Breast Cancer Research Foundation

OTHER

lead

Sanofi

INDUSTRY